ライフサイエンスコーパス: RXR

1 RXR agonist-induced antileukocyte adhesive effects seeme

2 RXR agonists also prevented TNF-alpha-induced VCAM-1 and

3 RXR agonists induced no beneficial effects in the E4FAD-

4 RXR antagonists completely prevented and RXR agonists we

5 RXR remains flexible and adaptive by maintaining loosely

6 RXR signaling is predicted to have a major impact in mac

7 (RXR)4-AcpP increased survival of mice infected with A. l

8 (RXR)4-AcpP reduced viability of A. lwoffii and A. bauman

9 RXR, EcR, and MfR agonists increased storage lipid accum

10 rigenic cells and primary hepatocytes, AEG-1/RXR colocalizes in the nucleus in which AEG-1 interferes

11 Accordingly, RXR-deficient myeloid cells are more efficient in promot

12 ES cells confirmed that bexarotene-activated RXR affected neuronal development at different levels, i

13 olecular mechanisms whereby ligand-activated RXR can affect or restore cognitive functions.

14 We conclude that bexarotene-activated RXRs promote genetic programs involved in the neurogenes

15 eceptor (VDR) and retinoid X receptor-alpha (RXR) has not been investigated.

16 For proliferator-activated receptor alpha/RXR-activated genes, the strongest response was TRG > 4-

17 Our findings are consistent with altered RXR::VDR binding contributing to immunity-related diseas

18 Although RXRs are obligate heterodimeric partners for PPAR action

19 t aortic SMCs were pretreated with either an RXR agonist (bexarotene or 9-cis retinoic acid) or vehic

20 RXR through modeling and then assayed in an RXR-RXR mammalian-2-hybrid (M2H) system and in RXR-respo

21 in these tetramers can separately bind to an RXR response element.

22 rodimer and binding of the heterodimer to an RXR-binding site on the Cln2 promoter.

23 Using an RXR-VDR mammalian two-hybrid (M2H) biologic assay system

24 and MerTK and treatment of the cells with an RXR agonist further induced their expression, coincident

25 he full agonist 9a at RXR (pEC50 of 8.2) and RXR-Nurr1.

26 eceptors retinoid X receptor (RXR)-alpha and RXR-beta in mouse epidermal keratinocytes (RXR-alphabeta

27 ed motifs corresponded to the ETS, EBOX, and RXR TR families.

28 ear receptors PPARgamma, PPARdelta, LXR, and RXR stimulated microglial phagocytosis in vitro and rapi

29 nsights into fundamental aspects of PPAR and RXR biology, and their actions in the vasculature, conti

30 RXR antagonists completely prevented and RXR agonists were more effective than RA in inducing neu

31 ed through synergistic activation of RAR and RXR nuclear receptors.

32 tissues where it acts by stimulating RAR and RXR receptors, RA signaling during development is absolu

33 as a novel homeostatic regulator of RXR and RXR/RAR that might contribute to hepatocarcinogenesis.

34 In this structure, both TR and RXR are in the active state conformation for optimal bin

35 VDR and RXR expression were assessed by immunohistochemical stai

36 p62 directly interacts with VDR and RXR promoting their heterodimerization, which is critica

37 onstrated interaction between betaCaMKII and RXRs, suggesting that CaMKII pathway regulates the activ

38 PPARs and RXRs are also involved directly in inflammatory and vasc

39 e data establishing a key role for PPARs and RXRs in energy balance, inflammation, and vascular biolo

40 less conserved: Sequences of THRs, RARs and RXRs were >/=90% similar to those of the human, ERs, AR,

41 It was thus reported that apo-RXR self-associates into tetramers and that each dimer w

42 Molecules that function as RXR agonists are of special interest for the prevention

43 ional assays, lead to the full agonist 9a at RXR (pEC50 of 8.2) and RXR-Nurr1.

44 SAR of sterically constricted benzofurans at RXR.

45 otein sequence identified an arginine-based (RXR) ER retention sequence located within intracellular

46 y were evaluated for their potential to bind RXR through modeling and then assayed in an RXR-RXR mamm

47 nuclear receptors, can also be activated by RXR agonists known as rexinoids.

48 e nuclear receptor Nurr1 can be activated by RXR via heterodimerization (RXR-Nurr1) and is a promisin

49 hat interdomain communication is affected by RXR in RXR:TR.

50 Hence, DNA binding by RXR tetramers may bring distant genomic regions into clo

51 ciations were not significantly different by RXR expression.

52 hibition of mammary carcinoma cell growth by RXR ligands stems from the ability of these compounds to

53 e repression of TR*T3:RXR transactivation by RXR agonists.

54 The approach's validity is underscored by RXR::VDR motif sequence being predictive of binding stre

55 y plastic to a compact form upon binding CAR:RXR.

56 ite on RXR alters the transactivation by CAR:RXR.

57 Functional CAR:RXR heterodimers recruit coactivator proteins, such as t

58 hrough both coactivator binding sites on CAR:RXR, which distinctly bind two SRC1 molecules.

59 VDR-BVs are enriched in consensus RXR::VDR binding motifs, yet most fell outside of these

60 cognizes peptide substrates of the consensus RXR(H/R)X(S/T); it accepts essentially any amino acid at

61 uences of C. sapidus and other arthropod EcR/RXR/USP analyzed by in silico indicates a plausible, str

62 between the nuclear receptor heterodimer EcR:RXR and MfR.

63 e requirement of ecdysone binding to the EcR:RXR:MfR complex to regulate lipid storage and that an ex

64 he recent discoveries of multiple endogenous RXR agonists that mediate physiological tasks such as li

65 nic hepatocytes, overexpressed AEG-1 entraps RXR in cytoplasm, precluding its nuclear translocation.

66 Our results suggest a mechanism to establish RXR therapeutic targets with significance in neurodegene

67 lls of the oligodendrocyte lineage expressed RXR-gamma in rat tissues that were undergoing remyelinat

68 5,11-(6H)dione (AM6-36) (3) is among the few RXR ligands known.

69 acidic moiety that is believed to be key for RXR activation.

70 These data suggest a broader role for RXR within heterodimers, whereas offering multiple strat

71 novel compounds demonstrate selectivity for RXR and minimal crossover onto the retinoic acid recepto

72 e and its distinct substrate specificity for RXR motifs surrounded by basic residues, we performed si

73 Furthermore, RXR agonists increased RXR/PPARgamma interaction, and co

74 reased binding of the nuclear receptors FXR, RXR, HNF4alpha, and LRH-1 to promoter response elements

75 anscriptional activation of lipogenesis, FXR-RXR, PPAR-alpha mediated lipid oxidation and oxidative s

76 Signaling via the retinoid X receptor gamma (RXR-gamma) has been shown to be a positive regulator of

77 and retinoic acid receptor-gamma (RAR-gamma)/RXR-beta are bound as repressing complexes to their cogn

78 mer is different from that of the PPAR-gamma-RXR-alpha heterodimer, even when both NR complexes are a

79 be activated by RXR via heterodimerization (RXR-Nurr1) and is a promising target for treating neurod

80 They serve as hallmarks for how RXR changes conformation and dynamics in the presence of

81 pecific expression of AQP2 and point to HOX, RXR, CREB and GATA family TRs as playing likely addition

82 ounds based on the interaction with a hybrid RXR and subsequent expression of a reporter luciferase g

83 Here, we identified RXR as an interacting partner of astrocyte-elevated gene

84 Overall, our results identify RXR as a regulator in the myeloid cell-assisted metastat

85 ver, 1 can provoke side effects by impacting RXR-dependent receptor pathways.

86 R-RXR mammalian-2-hybrid (M2H) system and in RXR-responsive element (RXRE)-mediated transcriptional e

87 approach to discover genome-wide changes in RXR cistrome (ChIP-Seq) and gene expression profile (RNA

88 nify an isoform-specific role for Akt/PKB in RXR-selective signaling to promote and to retain myoblas

89 erdomain communication is affected by RXR in RXR:TR.

90 es, thereby affecting signal transmission in RXR heterodimers.

91 Furthermore, RXR agonists increased RXR/PPARgamma interaction, and combinations of suboptima

92 We found bexarotene increased RXR binding to promoter regions in cortex of APOE3 mice.

93 Many individual RXR heterodimers have beneficial effects in vascular smo

94 Upon interaction, AEG-1 profoundly inhibited RXR/retinoic acid receptor (RAR)-mediated transcriptiona

95 e astrocyte elevated gene-1 (AEG-1) inhibits RXR-dependent transcription and activates NF-kappaB.

96 with retinoid X receptor (RXR) and inhibits RXR function.

97 wo ligand-dependent signalling pathways into RXR heterodimer-specific responses.

98 d RXR-beta in mouse epidermal keratinocytes (RXR-alphabeta(ep-/-)) or a topical application of active

99 In mice that lacked RXR-gamma, adult oligodendrocyte precursor cells efficie

100 Using these features, 387 liganded RXR-bound enhancers were linked to 226 genes, which pred

101 h datasets revealed that bexarotene-liganded RXR affected signaling pathways associated with neurogen

102 iogenic genes, including Vegfa, has liganded RXR-controlled enhancers and provides the macrophage wit

103 ide studies were carried out to map liganded RXR-mediated transcriptional changes, active binding sit

104 ched in both datasets revealed that liganded RXR affected signaling pathways associated with neurogen

105 In the absence of MafB, activated LXR/RXR fails to induce the expression of AIM, a protein tha

106 MafB mediates the oxidized LDL-activated LXR/RXR-induced expression of apoptosis inhibitor of macroph

107 RPA and pathway analysis identified LXR/RXR signaling, IL-10 signaling, and alternative macropha

108 ment." The top enriched pathways include LXR/RXR Activation and Atherosclerosis Signaling, etc.

109 eukin-6 (IL-6), IL-10 IL-1, IL-8, TREM1, LXR/RXR activation, and PPAR signaling and genes encoding of

110 in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces so

111 Agonists of nuclear receptors LXR:RXR and PPAR:RXR act to ameliorate AD-related cognitive

112 ctures of the LXRbeta homodimer and LXRalpha:RXR (retinoid X receptor) heterodimers explains differen

113 The macrophage RXR cistrome has 5200 genomic binding sites, which are n

114 use rexinoids can potently activate multiple RXR pathways, we hypothesized that treating SMCs with re

115 dic and nonacidic indenoisoquinolines as new RXR ligands.

116 Thus, our studies have uncovered a novel RXR-dependent innate immune regulatory pathway, suggesti

117 However, although the mechanism of action of RXR agonists remains unclear, a major concern for their

118 tiation and fusion through the activation of RXR and the regulation of Akt/PKB isoform-specific expre

119 ese functional studies, ligand activation of RXR inhibits the expression of antiviral genes including

120 r results indicate that ligand activation of RXR suppresses the nuclear translocation of beta-catenin

121 -1KO mice, we observed increased activity of RXR heterodimer partners, liver X receptor and peroxisom

122 ults suggest that the repressive activity of RXR on prometastatic genes is mediated primarily through

123 this study, we demonstrate that deletion of RXR in myeloid cells enhances lung metastasis formation

124 concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors.

125 s ligand binding induces the dissociation of RXR tetramers into dimers, it can alter gene expression

126 that compounds that trigger dissociation of RXR tetramers may comprise a novel class of anticarcinog

127 thway, suggesting that the downregulation of RXR expression or RXR antagonist treatment benefits host

128 in animals exposed to different effectors of RXR, EcR, and MfR signaling pathways, either individuall

129 ake them an attractive and unusual family of RXR agonists.

130 last differentiation due to the formation of RXR/liver X receptor (LXR) heterodimers, which induced e

131 additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage acti

132 thway that is mediated by the interaction of RXR motif and COPI.

133 Knockdown of RXR-gamma by RNA interference or RXR-specific antagonist

134 Loss of RXR function in hematopoietic cells resulted in formatio

135 the nuclear receptor (NR) binding partner of RXR-gamma has not been established.

136 mally addresses the ligand binding pocket of RXR.

137 es AEG-1 as a novel homeostatic regulator of RXR and RXR/RAR that might contribute to hepatocarcinoge

138 The significance of RXR for these functions was validated in mouse embryonic

139 To further validate the significance of RXR for these functions, we used mouse embryonic stem (E

140 ompounds to regulate the oligomeric state of RXR and is independent of the direct intrinsic transcrip

141 Pharmacological activation of RXRs inhibited osteoclast differentiation due to the for

142 t CaMKII pathway regulates the activities of RXRs.

143 Mice treated with >/=0.25 mg/kg of (RXR)4-AcpP survived longer and had less inflammation and

144 re we examine if the effect of bexarotene on RXR cistrome and transcriptomes depend on APOE isoform a

145 how that disrupting the SRC1 binding site on RXR alters the transactivation by CAR:RXR.

146 that the downregulation of RXR expression or RXR antagonist treatment benefits host antiviral respons

147 nockdown of RXR-gamma by RNA interference or RXR-specific antagonists severely inhibited oligodendroc

148 ers communicate with promoters via stable or RXR-induced loops and that some of the enhancers interac

149 can elicit side-effects by disrupting other RXR-heterodimer receptor pathways.

150 analogues also reducing inhibition of other RXR-dependent pathways (e.g., VDR-RXR).

151 europrotective role and indicated that other RXR ligands could have therapeutic potential in Parkinso

152 the VDR along with its heterodimeric partner RXR to the negative vitamin D response element on the pr

153 ion, ERK, activated by AEG-1, phosphorylates RXR that leads to its functional inactivation and attenu

154 l-UAB30, an analogue of 9cUAB30, is a potent RXR agonist but caused increased lipid biosynthesis unli

155 results suggest that modifications of potent RXR agonists such as NEt-TMN can lead to improved biolog

156 ctivators of the omega-3 LCPUFA sensing PPAR-RXR axis may influence retinal angiogenesis in NV AMD vi

157 This PPAR-RXR transcriptional complex plays a critical role in ene

158 Biological insights into PPAR-RXRs may help inform interpretation of clinical trials w

159 onists of nuclear receptors LXR:RXR and PPAR:RXR act to ameliorate AD-related cognitive impairment an

160 , likely as the result of enhanced PPARalpha/RXR activity and improved mitochondrial function.

161 ced PPARalpha/retinoid X receptor (PPARalpha/RXR) activity and downstream signaling pathways in glome

162 and in the C-terminus, organized as putative RXR motifs.

163 r "xenobiotic metabolism signaling" and "PXR/RXR activation" pathways.

164 viously demonstrated that retinoic acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers rec

165 The differential ability of RAR-RXR bound to DR0 compared to DR2, DR5, and DR8 to mediat

166 Recombinant RAR-RXR binds these non-canonical spacings in vitro with com

167 and topology of binding elements for the RAR-RXR heterodimer.

168 RAR/RXR and AhR pathways cross-talk at the levels of ligand-

169 The high-affinity Ajuba-RAR/RXR interaction site overlaps the region responsible for

170 RA effects are mediated by RAR/RXR receptors that we show are modified by interactions

171 dermal fibroblasts and is regulated via RAR/RXR-mediated pathways.

172 tivation by recruiting co-regulators and RAR:RXR or beta-catenin, suggesting an unexpected collaborat

173 ripts that encode the retinoid acid receptor RXR-gamma were differentially expressed during remyelina

174 he use of an agonist to the nuclear receptor RXR, bexarotene, as monotherapy against AD, presents pot

175 ers such as TR:9-cis retinoic acid receptor (RXR).

176 assessed for selective retinoid X receptor (RXR) agonism.

177 that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta

178 Examination of three retinoid X receptor (RXR) agonists [Targretin (TRG), UAB30, and 4-methyl-UAB3

179 ever, the expression of retinoid X receptor (RXR) alpha, peroxisomal proliferator-activated receptor

180 activate or antagonize retinoid X receptor (RXR) alpha.

181 liver X receptor (LXR)/retinoid X receptor (RXR) and farnesoid X receptor/RXR nuclear receptor signa

182 AEG-1 interacts with retinoid X receptor (RXR) and inhibits RXR function.

183 ch heterodimerizes with retinoid X receptor (RXR) and regulates transcription of target genes, such a

184 se of the activation of retinoid X receptor (RXR) at very low environmental concentrations.

185 ificantly decreased FXR/retinoid X receptor (RXR) binding affinity but enhanced the interaction of FX

186 itamin D receptor (VDR)-retinoid X receptor (RXR) complex and drove reporter gene transcription in re

187 te the nuclear receptor retinoid X receptor (RXR) display potent anticarcinogenic activities, but the

188 eptor-alpha (PPARalpha)/retinoid X receptor (RXR) heterodimer promotes transcription of genes involve

189 itamin D receptor (VDR)/retinoid X receptor (RXR) heterodimer that binds to two vitamin D response el

190 o RA receptor (RAR) and retinoid X receptor (RXR) heterodimers.

191 Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48

192 The retinoid X receptor (RXR) partners with numerous nuclear receptors, such as t

193 , in particular, of the retinoid X receptor (RXR) positioned nuclear receptors at the epicenter of th

194 Retinoid X receptor (RXR) regulates key cellular responses such as cell growt

195 Retinoid X receptor (RXR) regulates several key functions in myeloid cells, i

196 R) FokI AA genotype and retinoid X receptor (RXR) rs7861779 TT genotype were associated with increase

197 and evaluated for their retinoid X receptor (RXR) selective agonism.

198 acid receptor (RAR) and retinoid X receptor (RXR) to a dominant site in enhancer I and a subordinate

199 he LCPUFA-sensing PPARG-retinoid X receptor (RXR) transcription complex, may influence neovasculariza

200 igate heterodimers with retinoid X receptor (RXR), allowing integration of ligand-dependent signals a

201 receptor beta (TRbeta), retinoid X receptor (RXR), and PPARalpha.

202 receptors, such as the retinoid X receptor (RXR), are proteins that regulate a myriad of cellular pr

203 Activation of the retinoid X receptor (RXR), which is involved in cell proliferation, different

204 f the nuclear receptors retinoid X receptor (RXR)-alpha and RXR-beta in mouse epidermal keratinocytes

205 ranscription regulation retinoid X receptor (RXR)-liver X receptor (LXR) system.

206 gical processes through retinoid X receptor (RXR)-mediated gene expression, molecular pathways underl

207 erodimerization partner retinoid X receptor (RXR).

208 and Ultraspiracle (USP)/Retinoid-X Receptor (RXR).

209 a heterodimer with the Retinoid X receptor (RXR).

210 Because the effect of retinoid X receptor (RXR)alpha on arterial mononuclear leukocyte recruitment

211 ivated or antagonized retinoid "X" receptor (RXR) or PPARgamma in transient transfection assays.

212 acid receptors (RARs) and rexinoid receptor (RXRs) subtypes in a ligand-dependent manner.

213 in (agonist of the retinoid X acid receptor, RXR).

214 id X receptor (RXR) and farnesoid X receptor/RXR nuclear receptor signaling among pleiotropic genes a

215 Many liver X receptor/RXR-related genes (e.g., Scd-1 and Srebf1, which are ass

216 e androstane (CAR) and retinoid X receptors (RXR) are ligand-mediated transcription factors of the nu

217 selective agonist for Retinoid X receptors (RXR) improves cognitive deficits and amyloid-beta (Abeta

218 h heterodimerizes with retinoid X receptors (RXR).

219 a, -beta, -gamma), and retinoid X receptors (RXR-alpha, -beta, -gamma) was performed on tissue sample

220 eceptor (RAR-beta) and retinoid X receptors (RXR-beta, -gamma) was significantly upregulated in sebac

221 target retinoid and retinoic acid receptors (RXRs and RARs), leading to physiological and pharmacolog

222 Bexarotene-activated retinoid X receptors (RXRs) ameliorate memory deficits in Alzheimer's disease

223 s) heterodimerize with retinoid X receptors (RXRs) and bind to RA response elements (RAREs) in the re

224 e, we demonstrate that retinoid X receptors (RXRs) are key elements of the transcriptional program of

225 eptors (PPARs) and the retinoid X receptors (RXRs) are ligand-activated transcription factors that co

226 Retinoid X receptors (RXRs) are obligate partners for several other nuclear re

227 genesis, we found that retinoid X receptors (RXRs) control neuritogenesis.

228 d receptors (RARs) and retinoid X receptors (RXRs) in vitro.

229 ners of PPARgamma, the retinoid X receptors (RXRs), showed additive enhancement of the Abeta uptake t

230 ) signaling, including retinoid X receptors (RXRs).

231 s in coordination with retinoid X receptors (RXRs).

232 In this regard resonant x-ray reflectivity (RXR) provides a unique experimental tool to achieve exac

233 arginine residues separated by one residue (RXR motif).

234 s in the upstream stretch of basic residues (RXR motif) restored O-glycosylation and the cell surface

235 eral compounds also displayed more selective RXR activation with minimal cross-signaling of the retin

236 ervention through activation using selective RXR agonists (rexinoids).

237 led novel compounds, all analogues stimulate RXR-regulated transcription in mammalian 2 hybrid and RX

238 ctural mechanism for the repression of TR*T3:RXR transactivation by RXR agonists.

239 However, the structure of TR*T3 within TR*T3:RXR*9c is in a relative state of disorder, and the obser

240 that T3 dissociates more rapidly from TR*T3:RXR*9c than from TR*T3:RXR.

241 gment show lower affinities (K(a)) for TR*T3:RXR*9c than TR*T3:RXR.

242 ffinities (K(a)) for TR*T3:RXR*9c than TR*T3:RXR.

243 re rapidly from TR*T3:RXR*9c than from TR*T3:RXR.

244 scattering (SAXS) we show that the CAR(tcp):RXR(9c).SRC1 complex can encompass two SRC1 molecules co

245 wo SRC1 molecules compared with the CAR(tcp):RXR.SRC1, which binds only a single SRC1.

246 In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) i

247 titative co-localization with chromatin that RXR immobilization and co-localization with chromatin ar

248 These data demonstrate that RXR is a potent modulator of angiotensin II-mediated res

249 -delta (YBCO) thin film, we demonstrate that RXR is further capable to deliver site selectivity.

250 Our results indicate that RXR-gamma is a positive regulator of endogenous oligoden

251 This puts forward the possibility that RXR activation and increased levels of ABCA1 and ABCG1 c

252 Therefore, these results reveal that RXR agonists can inhibit the initial inflammatory respon

253 of osteoclast progenitor cells revealed that RXR homodimers directly target and bind to the Mafb prom

254 Our study reveals that RXR signaling mediates bone homeostasis and suggests tha

255 We show that RXR deficiency leads to transcriptomic changes in the lu

256 In this study we show that RXR-gamma binds to several NRs in OPCs and OLGs, one of

257 ogical and knockdown approaches we show that RXR-VDR signaling induces OPC differentiation and that V

258 The results showed that RXR ligands could increase neurotrophic signaling, but p

259 ether, the results of our study suggest that RXR antagonists, together with inhibitors of cell prolif

260 eric partners for PPAR action, the part that RXRs, and their endogenous retinoid mediators, exert in

261 mediates bone homeostasis and suggests that RXRs have potential as targets for the treatment of bone

262 The RXR motif was responsible for the interaction with coato

263 that, in vivo within their heterodimers, the RXR and RAR isotypes are not functionally redundant, and

264 ial for multicellular life, highlighting the RXR heterodimer and its associated ligands and transcrip

265 Administration of the RXR agonist 9-cis-retinoic acid to demyelinated cerebell

266 nt study, we investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apo

267 Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted i

268 are conserved in all x-ray structures of the RXR ligand-binding domain in the presence of agonist and

269 iciency was due to lack of expression of the RXR-dependent transcription factor v-maf musculoaponeuro

270 ganotin compounds and natural ligands of the RXR.

271 We reported previously that the RXR-type dibasic motif in the distal C-terminal tail of

272 s show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognit

273 lates critical steps of adipogenesis through RXR/PPARgamma and that prenatal TBT exposure predisposes

274 Thus, RXR activation stimulates physiological Abeta clearance

275 Thus, RXR agonists address the loss-of-function associated wit

276 Thus, RXR agonists may constitute a new therapeutic tool in th

277 Thus, RXRs are in the final common path and may be therapeutic

278 Agonist binding to RXR initiates a large conformational change in the recep

279 cruitment of transcriptional coactivators to RXR, preventing transcription of target genes.

280 Inhibition of co-activator recruitment to RXR and activation of NF-kappaB were identified to play

281 By applying a new analysis scheme to RXR, which takes the atomic structure of the material in

282 ve cooperativity in ligand binding within TR:RXR heterodimers.

283 ear receptor dimers, in which an unactivated RXR partner provides an inhibitory tail wrap to the cofa

284 ded heterodimers of vitamin D receptor (VDR)/RXR-alpha and retinoic acid receptor-gamma (RAR-gamma)/R

285 at -28 kb that 1,25D-dependently docked VDR, RXR, C/EBPbeta, and RUNX2.

286 n of other RXR-dependent pathways (e.g., VDR-RXR).

287 acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers recruit only one coactivator molecule

288 tingly, although 1,25(OH)(2)D(3) induced VDR/RXR binding to the VDRE-containing proximal promoter, th

289 e VDRE-containing proximal promoter, the VDR/RXR heterodimer also localized to a cluster of at least

290 eterodimerization, which is critical for VDR:RXR target gene recruitment.

291 The most effective PPMO tested was (RXR)4-AcpP, which is targeted to acpP.

292 nt benefits host antiviral response, whereas RXR agonist treatment may increase the risk of viral inf

293 RARs control multiple genes, whereas RXRs serve as partners for RARs and other nuclear recept

294 Further studies are vital to address whether RXR agonists are an APOE4-specific AD therapeutic and th

295 understood, this study investigated whether RXR agonists can affect this response and the underlying

296 e show an allosteric mechanism through which RXR co-operates with a permissive dimer partner, peroxis

297 While RXR can regulate gene expression due to its intrinsic li

298 The increase in bone mass associated with RXR deficiency was due to lack of expression of the RXR-

299 an umbilical arterial endothelial cells with RXR agonists such as bexarotene or 9-cis-retinoid acid.

300 d no significant effects on interaction with RXR.

301 LXRs interact/cooperate with RXRs and result in the activation of StAR gene transcrip